Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

140 enrolled

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Active not recruiting

155 enrolled

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT00838539 2018-09-18

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Phase 1 Completed

63 enrolled 26 charts

Tumor-Agnostic

Neoplasms

NCT01378377 2018-07-30

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Phase 1 Terminated

33 enrolled 21 charts

Tumor-Agnostic

Neoplasms

NCT00678769 2015-11-04

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Phase 1 Completed

72 enrolled

Tumor-Agnostic

Neoplasms

NCT01417065 2014-06-23

Temsirolimus In Phase 0

Phase EARLY_PHASE1 Completed

15 enrolled

Tumor-Agnostic

Neoplasms

NCT00290472 2014-05-23

CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2 Completed

89 enrolled 9 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00887640 2014-02-26

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

Phase 2 Terminated

11 enrolled 9 charts

Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT01079286 2013-07-15

I-NET

Phase 1 Completed

18 enrolled

Genitourinary

Carcinoma, Renal Cell, Neoplasms

NCT00062751 2011-04-15

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms

Phase 2 Completed

108 enrolled 4 charts

Breast

Breast Neoplasms, Neoplasms

Clinical Trials

TAPUR

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

Temsirolimus In Phase 0

CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

I-NET

Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms